Tags : ~$2B

Biotech

AbbVie to License I-Mab’s Lemzoparlimab (TJC4) for ~$2B

Shots: I-Mab to receive $180M upfront, $20M on P-I results, and is eligible to receive ~$1.74B which include $840M as development & regulatory milestones while remaining as commercial milestones along with royalties on sales of the therapy outside China AbbVie to get an exclusive global license (Ex-greater China) to develop and commercialize lemzoparlimab while I-Mab […]Read More